Eli Lilly shares rose over 6% to about $1,370, a record closing high, after third-quarter revenue jumped 39% year over year to $24.4 billion, above the LSEG consensus of $22.6 billion. Adjusted EPS rose 6.6% to $7.48, beating analysts' $6.26 estimate, though a sizable acquisition-related accounting charge held back annual profit growth. Adjusted gross margin reached 84.4%, up from 83.6% a year earlier. Mounjaro revenue climbed 65% to $10.7 billion and Zepbound rose 49% to $5.35 billion, as higher patient volumes more than offset lower realized prices. The price target was raised to $1,500 from $1,300 and the 2 rating was reiterated, with shares up more than 50% since the April 29 close.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
Eli Lillypharmaceuticalsearnings
Open a keyword to see other news on the same topic.
Related news
- Cramer sees opportunity amid tech turmoil and predicts a holiday win for FedEx
Stocks fell Thursday as weak results from several major technology companies weighed on the market, with Alphabet tumbling after missing revenue expectations despite strong Google Cloud growth, and Microsoft falling in the tech selloff despite accelerating Azure revenue growth. Jim Cramer said investors were indiscriminately selling strong companies alongside weaker ones. Eli Lilly shares hit an all-time high after a beat-and-raise quarter driven by demand for its obesity and diabetes treatments, with Lilly capturing 7 out of every 10 new participants in the Medicare GLP-1 Bridge program. FedEx beat quarterly expectations and raised its full-year outlook, but a softer fourth-quarter forecast kept gains in check, and Cramer predicted FedEx will surpass UPS for the first time in the holiday shipping season. FedEx Freight, spun off from FedEx in June, reports earnings after the bell.
- Lilly raises outlook for third time this year as Zepbound sales soar.
- Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly reported third-quarter adjusted earnings of $7.48 per share and revenue of $24.40 billion, both above analyst estimates of $6.26 and $22.61 billion. The company raised its 2026 revenue forecast to $91–92 billion from $85–87 billion, while its adjusted earnings outlook was lowered to $35–36 per share from $35.50–36.50, reflecting $4.57 per share in deal-related charges. Mounjaro revenue rose 65% to $10.72 billion and Zepbound reached $5.35 billion, up 49%, while the new obesity pill Foundayo brought in $184 million, below forecasts of about $229 million. Net income was $6.45 billion, or $7.22 per share, including those deal charges.
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Leads Industry
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
- Lilly’s Weight-Loss Machine Gets Even Bigger
Related markets
Latest news
- Nvidia's relationship with China just got even more complicated as report says Jensen Huang was target of spy plot
Nvidia has struggled to gain a foothold in China because of US Commerce Department export restrictions in place since 2022. The New York Times reported that US intelligence believes Alice Huang, a leader at Nvidia customer Megaspeed with a well-documented relationship with Jensen Huang, acted as an intelligence asset and passed information to China's governing party, raising questions about information leakage from Nvidia. In December 2025, the Trump administration allowed some H200 chip exports after a $5 million lobbying push during the year, but H200 sales made up less than 1% of Nvidia's $89 billion second-quarter data center revenue, as Beijing blocked Chinese buyers from purchasing Nvidia chips. Nvidia said its forward outlook includes no China data center compute revenue. The article also describes a black-market trade smuggling chips through Southeast Asia and Blackwell B300 chips being openly sold on Douyin at millions of US dollars per server.
- Big Oil earnings are set to surge. Why investors may want to be cautious
The article says earnings at ExxonMobil, Chevron, Marathon Petroleum and ConocoPhillips are set to rise sharply, with EPS for XOM, CVX and COP expected to more than double from a year earlier. Marathon Petroleum's EPS estimate is $25.37 per share, versus $4.51 a year ago, driven by higher oil prices and a large crack spread on refined products, with sales expected to rise by $13 billion in one year. The author argues that guidance and capital spending plans may matter more than the earnings figures themselves. Citing BTIG analyst Jonathan Krinsky, the article notes the S&P Refining Index has risen nearly 160% in 2026, its best year in at least three decades, and that he expects at least consolidation, with a significant downside reversion considered more likely.
- Okta vs. UiPath: Which Technology Stock Is a Better Buy in 2026?
The article compares Okta (OKTA) and UiPath (PATH), two software companies with different models: Okta provides identity and access management, while UiPath offers an automation platform. Okta reported FY 2026 revenue of nearly $2.9 billion, up about 11.8%, and net income of close to $235.0 million versus $28.0 million a year earlier; free cash flow was nearly $863.0 million, though stock-based compensation was roughly 61.5% of operating cash flow. UiPath posted revenue of roughly $1.6 billion, up about 12.7%, net income of nearly $282.3 million and free cash flow of approximately $352.2 million, with stock-based compensation at roughly 78.3% of operating cash flow. The piece outlines Okta's competition and cybersecurity risks and UiPath's reliance on a limited number of large customers, and the author leans toward Okta, citing growing demand for identity security.
- Microsoft (MSFT) Expands Copilot In Education, Is The AI Upside Already Priced In?
McGraw Hill launched a plugin for Microsoft 365 Copilot that ties Copilot use to higher education workflows and licensed digital course materials. Microsoft's share price return was 17.71% over 90 days and 57.03% over 3 years, while the 1-year total shareholder return was slightly down 1.14%. A Simply Wall St narrative puts fair value at $419.91, below the last close of $531.01, and suggests Copilot optimism and strong cloud results may already be heavily reflected in the stock. On the other side, the article cites return on equity of 30.2%, a net profit margin of 40.3%, and a valuation model showing the stock trading about 22.5% below its estimate of future cash flow value. It also notes the stock looks expensive against a peer P/E average of 24.8x and significant insider selling over the past three months.
- Can This Number Push Booking Holdings Stock Higher?
Booking's top Genius members (Levels 2 and 3) made up more than 30% of active customers and a high 50% share of room nights in the June quarter, both up from a year earlier. Direct room nights kept growing, with the direct share of consumer room nights in the mid-60% range, though pressure on unpaid search traffic continued and large language model traffic stayed well below 1% of room nights. Booking plans a $100 million investment in Vayo, a new company offering a personal travel agent, announced October 14, 2026. The stock (BKNG) fell 29.0% in the year to October 28, 2026, while the S&P 500 returned 14.0%. For the September quarter, management guided room nights up 3% to 5% and gross bookings and revenue up 4% to 6%, versus June-quarter gains of 9% and 8%.
- ServiceNow just can't seem to escape the SaaSpocalypse — even after strong Q3 AI growth
A panel discussed ServiceNow after its results, where free cash flow rose but remaining performance obligations (RPO) came in modestly below expectations, and the company itself forecasts RPO growth to slow in the fourth quarter. CFO Gina Mastrantonio said AI net new business grew 65% year over year, beating expectations, which allowed the company to raise its full-year AI target to 1.7 billion while delivering AI value without a large capex investment. Julia said the market is not yet convinced, citing concerns about AI reducing seat counts, while Mastrantonio said ServiceNow's blended pricing covers both seats and usage. The stock was down 25% that day, which the speakers noted was the fourth straight quarter shares fell after a report.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.